

L Number	Hits	Search Text	DB	Time stamp
1	1568	((544/283) or (544/284) or (544/287) or (514/266.21) or (514/266.23) or (514/266.3)).CCLS.	USPAT; US-PGPUB	2004/01/07 16:20
2	404	((544/283) or (544/284) or (544/287) or (514/266.21) or (514/266.23) or (514/266.3)).CCLS.) and (oxy or thio)	USPAT; US-PGPUB	2004/01/07 16:20

EAST
a/913,020

09/ 913,020

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded
NEWS 5 SEP 29 DISSABS now available on STN
NEWS 6 OCT 10 PCTFULL: Two new display fields added
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9 NOV 24 MSDS-CCOHS file reloaded
NEWS 10 DEC 08 CABA reloaded with left truncation
NEWS 11 DEC 08 IMS file names changed
NEWS 12 DEC 09 Experimental property data collected by CAS now available
in REGISTRY
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 14 DEC 17 DGENE: Two new display fields added
NEWS 15 DEC 18 BIOTECHNO no longer updated
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer
available
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS
databases
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19 DEC 22 ABI-INFORM now available on STN

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:51:55 ON 07 JAN 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

09/ 913,020

FILE 'REGISTRY' ENTERED AT 13:52:16 ON 07 JAN 2004 ✓
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2004 HIGHEST RN 634558-38-6
DICTIONARY FILE UPDATES: 5 JAN 2004 HIGHEST RN 634558-38-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading 09913020.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 13:52:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22537 TO ITERATE

100.0% PROCESSED 22537 ITERATIONS
SEARCH TIME: 00.00.01

389 ANSWERS

L2 389 SEA SSS FUL L1

=> file caplus

09/ 913,020

COST IN U.S. DOLLARS

SINCE FILE
ENTPV

TOTAL
SESSION

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:52:57 ON 07 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jan 2004 VOL 140 ISS 2
FILE LAST UPDATED: 6 Jan 2004 (20040106/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 8 L2

=> d l3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:610442 CAPLUS

DOCUMENT NUMBER: 139:164806

TITLE: Preparation of quinazolines as VEGF receptor inhibitors

INVENTOR(S): Hennequin, Laurent Francois Andre

PATENT ASSIGNEE(S): Astrazeneca R & D Sodertalje, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064413	A1	20030807	WO 2003-GB343	20030128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM



RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

EP 2002-290242 A 20020201

OTHER SOURCE(S) :
GI

CASREACT 139:164806; MARPAT 139:164806



AB The title compds. [I; ring C = indolyl, indazolyl or azaindolyl; Z = O, NH, S; n = 0-5; m = 0-3; R2 = H, OH, halo, etc.; R1 = H, halo, oxo, OH, etc.], useful in the manuf. of a medicament for use in the prodn. of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, were prepd. and formulated. E.g., a multi-step synthesis of II, was given. The compds. I inhibit the effects of VEGF, a property of value in the treatment of a no. of disease states including cancer and rheumatoid arthritis (no biol. data).

IT 574745-14-5P 574745-15-6P 574745-16-7P
 574745-17-8P 574745-18-9P 574745-19-0P
 574745-20-3P 574745-21-4P 574745-22-5P
 574745-23-6P 574745-24-7P 574745-25-8P
 574745-26-9P 574745-27-0P 574745-28-1P
 574745-29-2P 574745-30-5P 574745-31-6P
 574745-32-7P 574745-33-8P 574745-34-9P
 574745-35-0P 574745-36-1P 574745-37-2P
 574745-38-3P 574745-39-4P 574745-40-7P
 574745-41-8P 574745-42-9P 574745-43-0P
 574745-44-1P 574745-45-2P 574745-46-3P
 574745-47-4P 574745-48-5P 574745-49-6P
 574745-50-9P 574745-51-0P 574745-52-1P
 574745-53-2P 574745-54-3P 574745-55-4P
 574745-56-5P 574745-57-6P 574745-58-7P
 574745-59-8P 574745-61-2P 574745-62-3P
 574745-63-4P 574745-64-5P 574745-65-6P
 574745-66-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of quinazolines as VEGF inhibitors)

RN 574745-14-5 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[4-[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-


09/ 913,020

methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-15-6 CAPLUS

CN Piperazine, 1-[3-[[7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-6-quinazolinyl]oxy]propyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 574745-16-7 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-17-8 CAPLUS


CN Piperazine, 1-acetyl-4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-18-9 CAPLUS


09/ 913,020

CN Piperazine, 1-[3-[[7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 574745-19-0 CAPLUS

CN 2-Propyn-1-amine, N-[2-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 574745-20-3 CAPLUS


CN Piperazine, 1-acetyl-4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-21-4 CAPLUS


CN Piperazine, 1-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]propyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-22-5 CAPLUS

CN Piperazine, 1-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 574745-23-6 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-24-7 CAPLUS

CN Piperidine, 1-acetyl-4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 574745-25-8 CAPLUS

CN Pyrrolidine, 1-acetyl-2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (2S)- (9CI) (CA INDEX NAME)

09/ 913,020


Absolute stereochemistry.



RN 574745-26-9 CAPLUS


CN Pyrrolidine, 1-acetyl-2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-27-0 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[[1-(2,2,2-trifluoroethyl)-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 574745-28-1 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-29-2 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 574745-30-5 CAPLUS

CN Quinazoline, 7-[2-[4-(2-fluoroethyl)-1-piperazinyl]ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (9CI) (CA INDEX NAME)



RN 574745-31-6 CAPLUS


CN Piperazine, 1-acetyl-4-[2-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 574745-32-7 CAPLUS

CN Piperidine, 4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)


09/ 913,020



RN 574745-33-8 CAPLUS

CN Pyrrolidine, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-(2-methyl-1-oxopropyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574745-34-9 CAPLUS

CN Pyrrolidine, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-(2-methyl-1-oxopropyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574745-35-0 CAPLUS

CN Piperidine, 4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-(methanesulfonyl)- (9CI) (CA INDEX NAME)


09/ 913,020



RN 574745-36-1 CAPLUS

CN Pyrrolidine, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy)methyl]-1-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574745-37-2 CAPLUS

CN Pyrrolidine, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy)methyl]-1-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574745-38-3 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-39-4 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 574745-40-7 CAPLUS

CN Quinazoline, 7-[3-[4-(2-fluoroethyl)-1-piperazinyl]propoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (9CI) (CA INDEX NAME)



RN 574745-41-8 CAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 574745-42-9 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-(1H-indazol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-43-0 CAPLUS
CN Piperazine, 1-acetyl-4-[3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-44-1 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 574745-45-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-46-3 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-(1H-indazol-5-yloxy)-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-47-4 CAPLUS

CN 1-Piperazinecarboxamide, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-48-5 CAPLUS


CN 2,4-Imidazolidinedione, 3-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-5-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)



09/ 913,020


RN 574745-49-6 CAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 574745-50-9 CAPLUS

CN Piperidine, 1-acetyl-4-[[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 574745-51-0 CAPLUS


CN Piperidine, 1-acetyl-4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 574745-52-1 CAPLUS


CN Piperidine, 4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-53-2 CAPLUS

CN 2-Propyn-1-amine, N-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 574745-54-3 CAPLUS

CN Piperazine, 1-acetyl-4-[2-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 574745-55-4 CAPLUS


CN Piperazine, 1-acetyl-4-[3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-56-5 CAPLUS


09/ 913,020

CN Piperazine, 1-acetyl-4-[3-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-57-6 CAPLUS

CN 1-Piperazineacetamide, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-58-7 CAPLUS

CN 1-Piperazineacetamide, 4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-59-8 CAPLUS

CN Quinazoline, 7-[3-[4-(2-fluoroethyl)-1-piperazinyl]propoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)




09/ 913,020

RN 574745-61-2 CAPLUS


CN 1-Piperazineethanol, .alpha.-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(2-propynyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 574745-62-3 CAPLUS

CN Quinazoline, 7-[2-[4-(2-fluoroethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 574745-63-4 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)




RN 574745-64-5 CAPLUS

CN 1,4-Dioxa-8-azaspiro[4.5]decane-8-ethanol, .alpha.-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 913,020




RN 574745-65-6 CAPLUS
CN 1-Piperazineethanol, 4-acetyl-.alpha.-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 574745-66-7 CAPLUS
CN Piperidine, 1-[(dimethylamino)acetyl]-4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




IT 288387-52-0 574746-13-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of quinazolines as VEGF inhibitors)
RN 288387-52-0 CAPLUS
CN Quinazoline, 7-(3-bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)

09/ 913,020



RN 574746-13-7 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




IT 574745-67-8P 574745-68-9P 574745-69-0P
574745-70-3P 574745-75-8P 574745-76-9P
574745-77-0P 574745-79-2P 574745-80-5P
574745-81-6P 574745-82-7P 574745-83-8P
574745-84-9P 574745-85-0P 574745-86-1P
574745-87-2P 574745-88-3P 574745-89-4P
574745-90-7P 574745-92-9P 574745-99-6P
574746-00-2P 574746-03-5P 574746-04-6P
574746-05-7P 574746-06-8P 574746-08-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of quinazolines as VEGF inhibitors)

RN 574745-67-8 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 574745-68-9 CAPLUS


CN 6-Quinazolinol, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-69-0 CAPLUS

CN Quinazoline, 7-methoxy-6-(phenylmethoxy)-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)




RN 574745-70-3 CAPLUS

CN 6-Quinazolinol, 7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 574745-75-8 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 574745-76-9 CAPLUS


CN 7-Quinazolinol, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-77-0 CAPLUS

CN Quinazoline, 7-(3-bromopropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (9CI) (CA INDEX NAME)




RN 574745-79-2 CAPLUS

CN Quinazoline, 6-(3-bromopropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy- (9CI) (CA INDEX NAME)



RN 574745-80-5 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 574745-81-6 CAPLUS

CN 6-Quinazolinol, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy- (9CI) (CA


09/ 913,020

INDEX NAME)




RN 574745-82-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 574745-83-8 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)




RN 574745-84-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 913,020



RN 574745-85-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(2S)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574745-86-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 574745-87-2 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(2R)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)


09/ 913,020

Absolute stereochemistry.




RN 574745-88-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 574745-89-4 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 574745-90-7 CAPLUS


CN Quinazoline, 7-(2-bromoethoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (9CI) (CA INDEX NAME)

09/ 913,020




RN 574745-92-9 CAPLUS

CN Quinazoline, 7-[2-(2-bromoethoxy)ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (9CI) (CA INDEX NAME)




RN 574745-99-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 574746-00-2 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)




RN 574746-03-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-


09/ 913,020

methoxy-6-quinazolinyl]oxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 574746-04-6 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)




RN 574746-05-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 574746-06-8 CAPLUS


CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(4-piperidin-1-yloxy)- (9CI) (CA INDEX NAME)



09/ 913,020

RN 574746-08-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:434555 CAPLUS
DOCUMENT NUMBER: 139:22225
TITLE: Preparation of quinazoline compounds for the treatment of T cell mediated diseases
INVENTOR(S): Moore, Nelly Corine; Oldham, Keith
PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045943	A1	20030605	WO 2002-GB5182	20021120
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2001-28122 A 20011123
OTHER SOURCE(S): MARPAT 139:22225
GI



AB Quinazoline derivs. of formula I [Z = O, S, SO, SO₂, (substituted) CH₂; R₁ = halo, CF₃, CN, nitro, OH, SH, NH₂, CHO, alkanoyloxy, heterocyclalkyloxy, etc.; m = 0-3] are prepd. for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal. Thus, II was prepd. and tested for enzyme p56lck inhibition, T cell proliferation inhibition, skin graft rejection inhibition and anti-arthritis activity.


IT 474043-92-0P 474043-93-1P 474043-94-2P
 474043-95-3P 474043-96-4P 474043-97-5P
 474043-98-6P 474043-99-7P 474044-00-3P
 474044-01-4P 474044-02-5P 474044-03-6P
 474044-04-7P 474044-05-8P 474044-06-9P
 474044-07-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazoline compds. for treatment of T cell mediated diseases)

RN 474043-92-0 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474043-93-1 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 474043-94-2 CAPLUS

CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[2-(1-methyl-4-piperidiny)ethoxy]- (9CI) (CA INDEX NAME)



RN 474043-95-3 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)



RN 474043-96-4 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 474043-97-5 CAPLUS

CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474043-98-6 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy- (9CI) (CA INDEX NAME)



RN 474043-99-7 CAPLUS


CN Quinazoline, 4-[(5-bromo-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 474044-00-3 CAPLUS

CN Quinazoline, 4-[(5-bromo-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474044-01-4 CAPLUS


CN Quinazoline, 4-[(5-bromo-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474044-02-5 CAPLUS


CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 474044-03-6 CAPLUS

CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 474044-04-7 CAPLUS


CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 474044-05-8 CAPLUS


CN Quinazoline, 4-[(5-bromo-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)

09/ 913,020




RN 474044-06-9 CAPLUS

CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 474044-07-0 CAPLUS

CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(methylsulfonyl)propoxy] - (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:832791 CAPLUS

DOCUMENT NUMBER: 137:337908

TITLE: Preparation of antitumor quinazolines

INVENTOR(S): Ple, Patrick

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 73 pp.



CODEN: PIXXD2

09/ 913,020

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085895	A1	20021031	WO 2002-GB1734	20020415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2001-401007	A 20010419
OTHER SOURCE(S):			MARPAT 137:337908	

GI



AB The title compds. [I; Z = O, S, SO, etc.; m = 0-3; R1 = halo, CF3, CN, etc.; n = 0-3; R3 = halo, CF3, CN, etc.], useful in the manuf. of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease, were prepd. Thus, a multi-step synthesis of the quinazoline II, starting from 2-amino-4-benzyloxy-5-methoxybenzamide, was given. The compds. I show IC50 in the range of 0.001-10 .mu.M in in vitro c-Src kinase assay.

IT 474043-92-0P 474043-93-1P 474043-94-2P
474043-95-3P 474043-96-4P 474043-97-5P
474043-98-6P 474043-99-7P 474044-00-3P
474044-01-4P 474044-02-5P 474044-03-6P
474044-04-7P 474044-05-8P 474044-06-9P

09/ 913,020


474044-07-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antitumor quinazolines)


RN 474043-92-0 CAPLUS

CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 474043-93-1 CAPLUS

CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]- (9CI) (CA INDEX NAME)



RN 474043-94-2 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[2-(1-methyl-4-piperidiny)ethoxy]- (9CI) (CA INDEX NAME)



RN 474043-95-3 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 474043-96-4 CAPLUS

CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474043-97-5 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474043-98-6 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy- (9CI) (CA INDEX NAME)

09/ 913,020




RN 474043-99-7 CAPLUS

CN Quinazoline, 4-[[5-bromo-1,3-benzodioxol-4-yl]oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474044-00-3 CAPLUS


CN Quinazoline, 4-[[5-bromo-1,3-benzodioxol-4-yl]oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474044-01-4 CAPLUS


CN Quinazoline, 4-[[5-bromo-1,3-benzodioxol-4-yl]oxy]-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 474044-02-5 CAPLUS

CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 474044-03-6 CAPLUS


CN Quinazoline, 4-(1,3-benzodioxol-4-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 474044-04-7 CAPLUS

CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)


09/ 913,020




RN 474044-05-8 CAPLUS
CN Quinazoline, 4-[(5-bromo-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474044-06-9 CAPLUS
CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 474044-07-0 CAPLUS
CN Quinazoline, 4-[(5-chloro-1,3-benzodioxol-4-yl)oxy]-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:747609 CAPLUS

DOCUMENT NUMBER: 135:283196

TITLE: Therapeutic combinations of antihypertensive and antiangiogenic agents

INVENTOR(S): Curwen, Jon Owen; Ogilvie, Donald James

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074360	A1	20011011	WO 2001-GB1522	20010402
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1272186	A1	20030108	EP 2001-917305	20010402
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009729	A	20030204	BR 2001-9729	20010402
JP 2003528917	T2	20030930	JP 2001-572104	20010402
US 2003144298	A1	20030731	US 2002-240413	20021001
NO 2002004814	A	20021112	NO 2002-4814	20021004
PRIORITY APPLN. INFO.:			GB 2000-8269	A 20000405
			WO 2001-GB1522	W 20010402

OTHER SOURCE(S): MARPAT 135:283196

AB The invention concerns the use of a combination of an anti-angiogenic agent and an anti-hypertensive agent for use in the manuf. of a medicament for the treatment of a disease state assocd. with angiogenesis in a warm-blooded mammal, such as a human being. The invention also relates to pharmaceutical compns. comprising an anti-angiogenic agent and an anti-hypertensive agent, to kits thereof and to a method of treatment of a disease state assocd. with angiogenesis which comprises the administration of an effective amt. of a combination of an anti-angiogenic agent and an

anti-hypertensive agent to a warm-blooded animal, such as a human being. Anesthetized rats were dosed orally with 12.5 mg/kg of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline for 10 days, then they were dosed orally with 30 mg/kg captopril in addn. to quinazoline compd. The increase in diastolic blood pressure was reversed by the addn. of captopril.


IT 288383-14-2 288383-15-3 288383-16-4
288383-17-5 288383-18-6 288383-19-7
288383-20-0 288383-21-1 288383-22-2
288383-23-3 288383-24-4 288383-25-5
288383-26-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic combinations of antihypertensive and antiangiogenic agents)


RN 288383-14-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-15-3 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidiny)l)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-16-4 CAPLUS


CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288383-17-5 CAPLUS

CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 288383-18-6 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 288383-19-7 CAPLUS


CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 288383-20-0 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy] - (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-21-1 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-22-2 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 288383-23-3 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-24-4 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)


09/ 913,020



RN 288383-25-5 CAPLUS


CN 1-Pyrrolidineethanol, .alpha.-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-26-6 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:573671 CAPLUS

DOCUMENT NUMBER: 133:177183

TITLE: Preparation of quinazoline derivatives as angiogenesis inhibitors

INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren

PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.

SOURCE: PCT Int. Appl., 346 pp.

09/ 913,020

CODEN: PIXXD2

DOCUMENT TYPE:

Patent



LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1154774	A1	20011121	EP 2000-902730	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008128	A	20020213	BR 2000-8128	20000208
JP 2002536414	T2	20021029	JP 2000-598164	20000208
EE 200100409	A	20021216	EE 2001-409	20000208
AU 763618	B2	20030731	AU 2000-24475	20000208
ZA 2001006340	A	20021101	ZA 2001-6340	20010801
NO 2001003882	A	20011009	NO 2001-3882	20010809
PRIORITY APPLN. INFO.:			EP 1999-400305	A 19990210
			WO 2000-GB373	W 20000208
OTHER SOURCE(S):		MARPAT 133:177183		
GI				



AB The title compds. (I) [wherein A = an 8-, 9-, 10-, 12- or 13-membered bicyclic or tricyclic ring optionally contg. 1-3 O, N, and/or S heteroatoms; Z = O, NH, S, CH₂, or a bond; n = 0-5; m = 0-3; R₂ = H, OH, halo, CN, NO₂, CF₃, alkyl(sulfanyl), alkoxy, NR₃N₄, or R₅X₁; R₃ and R₄ = independently H or alkyl; X₁ = a bond, O, CH₂, OC(O), CO, S, SO, SO₂,

NR6CO, CONR7, SO2R8, NR9SO2, or NR10; R5 = H or (un)substituted alkyl, alkenyl, alkynyl, or heterocyclyl, etc.; R6-R10 = independently H or (alkoxy)alkyl were prep'd. for use in the prodn. of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. For instance, II was synthesized in a 9-step sequence starting with the cyclization of 2-amino-4-benzyloxy-5-methoxybenzamide using Gold's reagent in dioxane to form 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (84%). I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a no. of disease states including cancer and rheumatoid arthritis (no data).


IT **288382-08-1P**, 6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(angiogenesis inhibitor; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN **288382-08-1** CAPLUS

CN Quinazoline, 6-methoxy-7-[(1-methyl-3-piperidinyloxy)methoxy]-4-(7-quinolinylloxy)- (9CI) (CA INDEX NAME)



IT **288383-64-2P**, 7-Benzyloxy-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288383-65-3P**, 7-Hydroxy-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288384-15-6P**, 7-[2-(1-(tert-butoxycarbonyl)piperidin-4-yl)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288384-17-8P**, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-4-yl)ethoxy]quinazoline **288386-84-5P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)quinazoline


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(angiogenesis inhibitor; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN **288383-64-2** CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-65-3 CAPLUS

CN 7-Quinazolinol, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 288384-15-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 288384-17-8 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 288386-84-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-

yl)oxy]-7-quinazolinyl]oxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)



IT 288382-02-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288382-04-7P, 7-[3-(1,1-Dioxothiomo(rpholino)propoxy)-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288382-06-9P, 6-Methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-(quinolin-7-yloxy)quinazoline 288382-10-5P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-12-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(4-methylquinolin-7-yloxy)quinazoline 288382-14-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288382-16-1P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(quinolin-7-yloxy)quinazoline 288382-18-3P, 6-Methoxy-7-[[1-(2-(methylsulfonyl)ethyl)piperidin-4-yl]methoxy]-4-(quinolin-7-yloxy)quinazoline 288382-20-7P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-22-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-24-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-26-3P, 6-Methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-28-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-30-9P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288382-32-1P, 7-(3-(N,N-Dimethylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-34-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline 288382-36-5P, 7-[2-(N,N-Diethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-37-6P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-38-7P, 4-(2-Methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-39-8P, 4-(2-Methylindol-5-yloxy)-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-40-1P, 4-(2-Methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-41-2P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline 288382-42-3P, 7-[3-(Methylsulfonyl)propoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-43-4P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288382-44-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-45-6P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-46-7P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288382-47-8P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-48-9P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-49-0P, 7-[3-(Ethylsulfonyl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-50-3P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-51-4P, 7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline

288382-52-5P, 7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-53-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methylamino)ethoxy]quinazoline 288382-54-7P, 7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-55-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-56-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-57-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-58-1P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-59-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-methylsulfonylpropoxy)quinazoline 288382-60-5P, 7-[(1-(Cyanomethyl)piperidin-4-yl)methoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-61-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288382-62-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline 288382-63-8P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-64-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288382-65-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288382-66-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-67-2P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-68-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-69-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy]quinazoline 288382-70-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-71-8P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-72-9P, 288382-73-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288382-74-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-75-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-4-yloxy)ethoxy]quinazoline 288382-76-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methyl-N-methylsulfonylamino)ethoxy]quinazoline 288382-77-4P, 7-[2-[1-(2-Cyanoethyl)piperidin-4-yl]oxy]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-78-5P, 4-(2-Methylindol-5-yloxy)-7-[3-(pyrrolidinyl)propoxy]quinazoline 288382-79-6P, 4-(2-Methylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288382-80-9P, 4-(2-Methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-81-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288382-82-1P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-83-2P, 7-[3-(N,N-Diethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-84-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-85-4P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-86-5P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-87-6P, 7-[1-(2-Methoxyethyl)piperidin-4-yl]methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-88-7P, 7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-89-8P, 7-[2-[1-(2-Methoxyethyl)piperidin-4-yl]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-90-1P, 7-(2-Hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-91-2P, 7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-92-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-93-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-94-5P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-

morpholinopropoxy)quinazoline 288382-95-6P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288382-96-7P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288382-97-8P, 4-(4-Bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-98-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-[2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl]methoxy]quinazoline 288382-99-0P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-00-6P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-01-7P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-02-8P, (S)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-03-9P, (S)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-04-0P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-05-1P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-06-2P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-07-3P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-08-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-morpholinoethyl)piperidin-4-yl]methoxy]quinazoline 288383-09-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-10-8P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-11-9P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)quinazoline 288383-12-0P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288383-13-1P, 4-(6-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-14-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-15-3P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-16-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-17-5P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-18-6P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-19-7P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-20-0P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-21-1P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-22-2P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-23-3P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-24-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-25-5P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline 288383-26-6P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-27-7P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-6-yloxy)quinazoline 288383-29-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-morpholinopropoxy)quinazoline 288383-33-5P, 6,7-Dimethoxy-4-(quinolin-7-yloxy)quinazoline 288383-34-6P, (S)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-35-7P, (R)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-37-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-methylsulfonyl)ethyl]piperidin-4-yl]methoxy]quinazoline 288383-38-0P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-39-1P,

6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-40-4P,
 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-41-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]quinazoline 288383-42-6P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]quinazoline 288383-43-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-6-yloxy)quinazoline 288383-50-6P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-52-8P, 6-Methoxy-4-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-53-9P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-54-0P, 6-Methoxy-4-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-58-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-60-8P, 6-Methoxy-4-(2-methylquinolin-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-61-9P, 6-Methoxy-7-[(1-(2-methylsulfonyl)ethyl)piperidin-4-yl)methoxy]-4-(2-methylquinolin-7-yloxy)quinazoline 288383-63-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-66-4P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288383-67-5P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-68-6P, 7-[2-(N,N-Dimethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-70-0P, 6-Methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-75-5P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy]quinazoline 288383-76-6P, 6-Methoxy-7-[[1-(2-methoxyethyl)piperidin-4-yl)methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-81-3P, 7-(3-Chloropropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-82-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy]ethoxy]quinazoline 288383-84-6P, 6-Methoxy-4-(indol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-88-0P, 4-(2-Methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288383-89-1P, 4-(2-Methylindol-5-yloxy)-7-[3-(piperidin-1-yl)propoxy]quinazoline 288383-90-4P, 7-[(1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-92-6P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288383-94-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288383-95-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288383-96-0P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-97-1P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-98-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline 288383-99-3P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-oxopyrrolidin-1-yl)ethoxy]quinazoline 288384-00-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288384-01-0P, 4-(2,3-Dimethylindol-5-yloxy)-7-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-6-methoxyquinazoline 288384-02-1P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-03-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-04-3P, 4-(2,3-Dimethylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]-6-methoxyquinazoline 288384-05-4P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288384-06-5P,

4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline **288384-08-7P**, 7-Benzyloxy-4-(indol-5-yloxy)-6-methoxyquinazoline **288384-09-8P**, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288384-10-1P**, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-yl)quinazoline **288384-11-2P**, 4-(Indol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline **288384-12-3P**, 4-(Indol-6-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline **288384-14-5P**, 4-(2,3-Dimethylindol-5-yloxy)-7-(3-ethylsulfonylpropoxy)-6-methoxyquinazoline **288384-16-7P**, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-(3-morpholinopropoxy)quinazoline **288384-39-4P**, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline **288384-40-7P**, 4-(1,2-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline **288384-42-9P**, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline **288384-49-6P**, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline **288384-50-9P**, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(quinolin-7-yloxy)quinazoline **288384-51-0P**, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(4-methylquinolin-7-yloxy)quinazoline **288384-52-1P**, 6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(4-trifluoromethylquinolin-7-yloxy)quinazoline **288384-57-6P**, 4-(3-Fluoro-2-methylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline **288384-59-8P**, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline **288384-63-4P**, 4-(6-Methoxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288384-64-5P**, 4-(Indol-4-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288384-65-6P**, 4-(9H-Carbazol-3-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288384-67-8P**, 4-[[7-Chloro-2-(ethoxycarbonyl)indol-5-yl]oxy]-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288384-69-0P**, 7-Benzyloxy-4-[(1-tert-butoxycarbonyl-2,3-dimethylindol-5-yl)oxy]-6-methoxyquinazoline **288384-70-3P**, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-2-yloxy)quinazoline **288384-71-4P**, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-5-yloxy)quinazoline **288384-75-8P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline **288384-76-9P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline **288384-78-1P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline **288384-82-7P**, 4-(2-Carboxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288384-84-9P**, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(quinolin-7-yloxy)quinazoline **288384-85-0P**, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline **288384-87-2P**, 6-Methoxy-4-[(2-methyl-1,3-benzothiazol-5-yl)oxy]-7-(3-methylsulfonylpropoxy)quinazoline **288384-93-0P**, 4-(2-Chloro-1H-benzimidazol-6-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline **288384-95-2P**, 6-Methoxy-4-(2-methyl-1H-benzimidazol-6-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline **288385-00-2P**, 4-(3-Cyanoquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline **288385-10-4P**, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1,2,3,4-tetrahydroquinolin-6-yloxy)quinazoline **288385-18-2P**, 4-(2,3-Dihydro-1H-indol-5-yl)oxy-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline **288385-27-3P**, 6-Methoxy-7-(2-piperidinoethoxy)-4-(quinolin-7-yloxy)quinazoline **288385-30-8P**, 7-Benzyloxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline **288385-33-1P**, 7-Hydroxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline **288385-35-3P**, 6-Methoxy-7-(2-morpholinoethoxy)-4-(quinolin-7-yloxy)quinazoline **288385-38-6P**, (S)-6-Methoxy-7-(5-oxopyrrolidin-2-yl)methoxy-4-(quinolin-7-yloxy)quinazoline **288385-39-7P**, 4-(9H-Carbazol-2-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline **288385-86-4P**,


7-[[1-(Cyanomethyl)piperidin-4-yl]methoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288386-17-4P**, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline **288386-24-3P**, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline **288386-27-6P**, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288386-31-2P**, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline **288386-32-3P**, 4-(Indol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline **288386-33-4P**, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline **288386-34-5P**, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline **288386-36-7P**, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline **288386-68-5P**, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-methyl-2-oxopiperidin-4-yl)methoxy)quinazoline **288386-73-2P**, (R)-7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288386-77-6P**, 7-Hydroxy-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288386-79-8P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline **288386-81-2P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline **288386-88-9P**, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288386-90-3P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline **288386-92-5P**, 7-((1-(Cyanomethyl)piperidin-4-yl)methoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288386-94-7P**, (R)-6-Methoxy-4-(3-methylindol-5-yloxy)-7-(oxiran-2-ylmethoxy)quinazoline **288386-97-0P**, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288386-99-2P**, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-01-9P**, (R)-7-(2-Hydroxy-3-dimethylaminopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-03-1P**, (R)-7-[2-Hydroxy-3-(N,N-diethylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-05-3P**, (R)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-07-5P**, (R)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-09-7P**, (R)-7-[2-Hydroxy-3-(3-morpholinopropylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-11-1P**, (R)-7-[2-Hydroxy-3-[(3-(4-methylpiperazin-1-yl)propyl)amino]propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-13-3P**, (R)-7-[2-Hydroxy-3-[[3-(pyrrolidin-1-yl)propyl]amino]propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-19-9P**, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline **288387-23-5P**, (R)-7-(2-Hydroxy-3-dimethylaminopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline **288387-25-7P**, (R)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288387-29-1P**, (S)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288387-31-5P**, (S)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline **288387-33-7P**, (S)-7-(2-Hydroxy-3-dimethylaminopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline **288387-35-9P**, (R)-7-(2-Hydroxy-3-(isopropylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline **288387-37-1P**, (S)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288387-41-7P**, (S)-7-(2-Hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288387-42-8P**, (S)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288387-43-9P**, (R)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288387-44-0P**, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline **288387-45-1P**, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-(2-piperidinopropoxy)quinazoline

09/ 913,020

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(angiogenesis inhibitor; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)


RN 288382-02-5 CAPLUS

CN Quinazoline, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-(7-quinolinyloxy)- (9CI) (CA INDEX NAME)




RN 288382-04-7 CAPLUS

CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-(7-quinolinyloxy)- (9CI) (CA INDEX NAME)



RN 288382-06-9 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-(7-quinolinyloxy)- (9CI) (CA INDEX NAME)



RN 288382-10-5 CAPLUS


CN Quinazoline, 4-[(4-chloro-7-quinolinyloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-12-7 CAPLUS

CN Quinazoline, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-[(4-methyl-7-quinolinyl)oxy]- (9CI) (CA INDEX NAME)



RN 288382-14-9 CAPLUS


CN Quinazoline, 6-methoxy-4-[(4-methyl-7-quinolinyl)oxy]-7-[3-(1-methylpyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288382-16-1 CAPLUS


CN Quinazoline, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(7-quinolinyl)oxy- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-18-3 CAPLUS

CN Quinazoline, 6-methoxy-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]-4-(7-quinolinyl)oxy)- (9CI) (CA INDEX NAME)




RN 288382-20-7 CAPLUS

CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 288382-22-9 CAPLUS


CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288382-24-1 CAPLUS


09/ 913,020

CN Quinazoline, 6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]-4-[[2-(trifluoromethyl)-1H-indol-5-yl]oxy] - (9CI) (CA INDEX NAME)




RN 288382-26-3 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-pyrrolidiny)propoxy]-4-[[2-(trifluoromethyl)-1H-indol-5-yl]oxy] - (9CI) (CA INDEX NAME)



RN 288382-28-5 CAPLUS


CN Quinazoline, 4-[(3-fluoro-7-quinolinyl)oxy]-6-methoxy-7-[(1-methyl-3-piperidiny)methoxy] - (9CI) (CA INDEX NAME)



RN 288382-30-9 CAPLUS


CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(methylsulfonyl)propoxy] - (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-32-1 CAPLUS

CN 1-Propanamine, 3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 288382-34-3 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-[2-(4-morpholinyl)ethoxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 288382-36-5 CAPLUS


CN Ethanamine, N,N-diethyl-2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 288382-37-6 CAPLUS


09/ 913,020

CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-(7-quinolinyl)oxy)-
(9CI) (CA INDEX NAME)




RN 288382-38-7 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]-
(9CI) (CA INDEX NAME)




RN 288382-39-8 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)ethoxy]-
(9CI) (CA INDEX NAME)



RN 288382-40-1 CAPLUS


CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288382-41-2 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-[[6-(trifluoromethyl)-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 288382-42-3 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288382-43-4 CAPLUS


CN 1-Propanamine, 3-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 288382-44-5 CAPLUS


CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-45-6 CAPLUS

CN Ethanamine, N,N-diethyl-2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-(9CI) (CA INDEX NAME)




RN 288382-46-7 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(2-piperidinyl)ethoxy]-(9CI) (CA INDEX NAME)



RN 288382-47-8 CAPLUS


CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]-(9CI) (CA INDEX NAME)



09/ 913,020


RN 288382-48-9 CAPLUS

CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]-
(9CI) (CA INDEX NAME)




RN 288382-49-0 CAPLUS

CN Quinazoline, 7-[3-(ethylsulfonyl)propoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 288382-50-3 CAPLUS


CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)



RN 288382-51-4 CAPLUS


CN 1-Piperidineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-52-5 CAPLUS

CN 1-Piperazineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 288382-53-6 CAPLUS

CN Ethanamine, 2-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 288382-54-7 CAPLUS


CN 2-Propanol, 1-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288382-55-8 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-(7-quinolinyl)oxy)-(9CI) (CA INDEX NAME)




RN 288382-56-9 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(1-methyl-4-piperidinyl)methoxy]-(9CI) (CA INDEX NAME)



RN 288382-57-0 CAPLUS


CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-(9CI) (CA INDEX NAME)



RN 288382-58-1 CAPLUS


CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-(9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-59-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288382-60-5 CAPLUS

CN 1-Piperidineacetonitrile, 4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 288382-61-6 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 288382-62-7 CAPLUS


09/ 913,020

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 288382-63-8 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(1-methyl-3-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 288382-64-9 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 288382-65-0 CAPLUS


CN 4-Pyridinamine, N-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-66-1 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288382-67-2 CAPLUS

CN Quinazoline, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 288382-68-3 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 288382-69-4 CAPLUS


09/ 913,020

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-[2-(4-methyl-1-piperazinyl)ethoxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 288382-70-7 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288382-71-8 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288382-72-9 CAPLUS


CN 2-Propenamide, 3-[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288382-73-0 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288382-74-1 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 288382-75-2 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-piperidinyl)ethoxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 288382-76-3 CAPLUS


CN Methanesulfonamide, N-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-77-4 CAPLUS

CN 1-Piperidinepropanenitrile, 4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 288382-78-5 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288382-79-6 CAPLUS


CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288382-80-9 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)-
(9CI) (CA INDEX NAME)




RN 288382-81-0 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-
(9CI) (CA INDEX NAME)



RN 288382-82-1 CAPLUS


CN 1-Propanamine, 3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-N,N-
dimethyl- (9CI) (CA INDEX NAME)



RN 288382-83-2 CAPLUS


CN 1-Propanamine, N,N-diethyl-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-
quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288382-84-3 CAPLUS

CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 288382-85-4 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-pyridinyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 288382-86-5 CAPLUS

CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(1-piperidinyloxy)propoxy]- (9CI) (CA INDEX NAME)




RN 288382-87-6 CAPLUS

CN Quinazoline, 7-[[1-(2-methoxyethyl)-4-piperidinyloxy]methoxy]-4-[(2-methyl-1H-


09/ 913,020

indol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 288382-88-7 CAPLUS

CN 4-Morpholineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 288382-89-8 CAPLUS

CN Quinazoline, 6-methoxy-7-[2-[1-(2-methoxyethyl)-4-piperidinyl]ethoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 288382-90-1 CAPLUS


CN 1-Pyrrolidineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288382-91-2 CAPLUS

CN 2-Propanol, 1-(diethylamino)-3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-(9CI) (CA INDEX NAME)




RN 288382-92-3 CAPLUS

CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-(9CI) (CA INDEX NAME)



RN 288382-93-4 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-pyridinyloxy)ethoxy]-(9CI) (CA INDEX NAME)



RN 288382-94-5 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]-(9CI) (CA INDEX NAME)


09/ 913,020



RN 288382-95-6 CAPLUS

CN 1-Piperidineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288382-96-7 CAPLUS

CN 2-Pyrrolidinone, 5-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288382-97-8 CAPLUS


CN Quinazoline, 4-[(4-bromo-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020



RN 288382-98-9 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[[1-[2-(1-pyrrolidinyl)ethyl]-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 288382-99-0 CAPLUS

CN 1-Pyrrolidineethanol, .alpha.-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288383-00-6 CAPLUS

CN 4-Morpholineethanol, .alpha.-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 913,020



RN 288383-01-7 CAPLUS

CN 1-Piperidineethanol, .alpha.-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-02-8 CAPLUS

CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288383-03-9 CAPLUS

CN 1-Piperidineethanol, .alpha.-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

09/ 913,020


Absolute stereochemistry.



RN 288383-04-0 CAPLUS

CN 1-Piperidineethanol, .alpha.-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-05-1 CAPLUS

CN 1-Pyrrolidineethanol, .alpha.-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 913,020

RN 288383-06-2 CAPLUS

CN 1-Pyrrolidineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-07-3 CAPLUS


CN 1-Piperazineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-4-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-08-4 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 288383-09-5 CAPLUS


09/ 913,020

CN Quinazoline, 4-[(3-fluoro-7-quinolinyl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-10-8 CAPLUS

CN Quinazoline, 4-[(3-fluoro-7-quinolinyl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-11-9 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-6-yloxy)- (9CI) (CA INDEX NAME)




RN 288383-12-0 CAPLUS

CN 1-Piperidineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 913,020




RN 288383-13-1 CAPLUS

CN Quinazoline, 4-[(6-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-14-2 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-15-3 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)


09/ 913,020




RN 288383-16-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-17-5 CAPLUS
CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-18-6 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-19-7 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)


09/ 913,020




RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-21-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-22-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 288383-23-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-


09/ 913,020

methyl-1-piperazinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 288383-24-4 CAPLUS


CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy] - (9CI) (CA INDEX NAME)



RN 288383-25-5 CAPLUS

CN 1-Pyrrolidineethanol, .alpha.-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-26-6 CAPLUS


CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy] - (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-27-7 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-(6-quinolinylloxy)-
(9CI) (CA INDEX NAME)




RN 288383-29-9 CAPLUS

CN Quinazoline, 6-methoxy-4-[(4-methyl-7-quinolinyl)oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-33-5 CAPLUS

CN Quinazoline, 6,7-dimethoxy-4-(7-quinolinylloxy)- (9CI) (CA INDEX NAME)




RN 288383-34-6 CAPLUS

09/ 913,020

CN Quinazoline, 6-methoxy-7-[[[(3S)-1-methyl-3-piperidinyl]methoxy]-4-(7-quinolinyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-35-7 CAPLUS


CN Quinazoline, 6-methoxy-7-[[[(3R)-1-methyl-3-piperidinyl]methoxy]-4-(7-quinolinyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-37-9 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)




RN 288383-38-0 CAPLUS

CN Quinazoline, 4-[(1,2-dihydro-2,2,4-trimethyl-6-quinolinyl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)


09/ 913,020



RN 288383-39-1 CAPLUS
CN Quinazoline, 4-[(1,2-dihydro-2,2,4-trimethyl-6-quinolinyl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 288383-40-4 CAPLUS
CN Quinazoline, 4-[(2,4-dimethyl-7-quinolinyl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 288383-41-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-42-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy] - (9CI) (CA INDEX NAME)




RN 288383-43-7 CAPLUS

CN Quinazoline, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-(6-quinolinyloxy) - (9CI) (CA INDEX NAME)



RN 288383-50-6 CAPLUS


CN 4H-1-Benzopyran-4-one, 7-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288383-52-8 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]oxy]-4-methyl- (9CI) (CA INDEX NAME)




RN 288383-53-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 288383-54-0 CAPLUS


CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 288383-58-4 CAPLUS


CN Quinazoline, 4-[(2,4-dimethyl-7-quinolinyl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-60-8 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-7-quinolinyl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-61-9 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-7-quinolinyl)oxy]-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 288383-63-1 CAPLUS


CN Quinazoline, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-[(2-methyl-7-quinolinyl)oxy]- (9CI) (CA INDEX NAME)



RN 288383-66-4 CAPLUS


09/ 913,020

CN Quinazoline, 6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-[[2-(trifluoromethyl)-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 288383-67-5 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-7-quinolinyl)oxy]-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-68-6 CAPLUS


CN Ethanamine, 2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 288383-70-0 CAPLUS


CN Ethanamine, N-(2-methoxyethyl)-2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N-methyl- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-75-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 288383-76-6 CAPLUS

CN Quinazoline, 6-methoxy-7-[[[1-(2-methoxyethyl)-4-piperidinyl]methoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 288383-81-3 CAPLUS


CN Quinazoline, 7-(3-chloropropoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288383-82-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyloxy]ethoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 288383-84-6 CAPLUS

CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-(9CI) (CA INDEX NAME)



RN 288383-88-0 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-morpholinyl)ethoxy]-(9CI) (CA INDEX NAME)




RN 288383-89-1 CAPLUS


CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyloxy)propoxy]-(9CI) (CA INDEX NAME)

Cc1c[nH]c2cc(oc3ncnc4cc(OCCCN5CCCCC5)ccc34)ccc12


1-Piperidinedicarboxylic acid, 4-[[[4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




09/ 913,020

CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 288383-96-0 CAPLUS

CN Ethanamine, 2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 288383-97-1 CAPLUS


CN Ethanamine, 2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 288383-98-2 CAPLUS


CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-99-3 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 288384-00-9 CAPLUS


CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(2-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 288384-01-0 CAPLUS


CN 2,5-Pyrrolidinedione, 1-[2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-02-1 CAPLUS

CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288384-03-2 CAPLUS


CN Ethanamine, N-[2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 288384-04-3 CAPLUS


CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-05-4 CAPLUS

CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(4-pyridinyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 288384-06-5 CAPLUS


CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288384-08-7 CAPLUS


CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)

09/ 913,020



RN 288384-09-8 CAPLUS


CN Ethanamine, 2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 288384-10-1 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 288384-11-2 CAPLUS

CN Ethanamine, N-[2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)


09/ 913,020



RN 288384-12-3 CAPLUS
CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(methylsulfonyl)propoxy]-
(9CI) (CA INDEX NAME)




RN 288384-14-5 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-7-[3-(ethylsulfonyl)propoxy]-6-methoxy- (9CI) (CA INDEX NAME)




RN 288384-16-7 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-39-4 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288384-40-7 CAPLUS


CN Quinazoline, 4-[(1,2-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288384-42-9 CAPLUS

CN Methanesulfonamide, N-[3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)


09/ 913,020



RN 288384-49-6 CAPLUS
CN Methanesulfonamide, N-[3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 288384-50-9 CAPLUS
CN Methanesulfonamide, N-[3-[[6-methoxy-4-(7-quinolinyl)oxy]-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 288384-51-0 CAPLUS
CN Methanesulfonamide, N-[3-[[6-methoxy-4-[(4-methyl-7-quinolinyl)oxy]-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-52-1 CAPLUS

CN Quinazoline, 6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-4-[[4-(trifluoromethyl)-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 288384-57-6 CAPLUS


CN Quinazoline, 4-[(3-fluoro-2-methyl-7-quinolinyl)oxy]-6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 288384-59-8 CAPLUS


CN Methanesulfonamide, N-[3-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-63-4 CAPLUS

CN Quinazoline, 6-methoxy-4-[(6-methoxy-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288384-64-5 CAPLUS


CN Quinazoline, 4-(1H-indol-4-yloxy)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288384-65-6 CAPLUS


CN 9H-Carbazole, 3-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-67-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-chloro-5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 288384-69-0 CAPLUS


CN 1H-Indole-1-carboxylic acid, 5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-2,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 288384-70-3 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-(2-quinolinyl)oxy- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-71-4 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-(5-quinolinyl)oxy-
(9CI) (CA INDEX NAME)




RN 288384-75-8 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288384-76-9 CAPLUS


CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



09/ 913,020


RN 288384-78-1 CAPLUS

CN Methanesulfonamide, N-[3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 288384-82-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 288384-84-9 CAPLUS


CN Quinazoline, 6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-(7-quinolinyl)oxy)- (9CI) (CA INDEX NAME)



RN 288384-85-0 CAPLUS


CN Quinazoline, 4-[(4-chloro-7-quinolinyl)oxy]-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-87-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-5-benzothiazolyl)oxy]-7-[3-(methylsulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288384-93-0 CAPLUS


CN Quinazoline, 4-[(2-chloro-1H-benzimidazol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 288384-95-2 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-benzimidazol-5-yl)oxy]-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288385-00-2 CAPLUS

CN 3-Quinolinecarbonitrile, 7-[[6-methoxy-7-[(1-methyl-4-piperidiny) methoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 288385-10-4 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-[(1,2,3,4-tetrahydro-6-quinolinyl)oxy]- (9CI) (CA INDEX NAME)



RN 288385-18-2 CAPLUS


CN Quinazoline, 4-[(2,3-dihydro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288385-27-3 CAPLUS


09/ 913,020

CN Quinazoline, 6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-(7-quinolinyloxy)-
(9CI) (CA INDEX NAME)




RN 288385-30-8 CAPLUS

CN Quinazoline, 6-methoxy-7-(phenylmethoxy)-4-(7-quinolinyloxy)- (9CI) (CA
INDEX NAME)




RN 288385-33-1 CAPLUS

CN 7-Quinazolinol, 6-methoxy-4-(7-quinolinyloxy)- (9CI) (CA INDEX NAME)



RN 288385-35-3 CAPLUS

CN Quinazoline, 6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-(7-quinolinyloxy)-
(9CI) (CA INDEX NAME)




RN 288385-38-6 CAPLUS

09/ 913,020


CN 2-Pyrrolidinone, 5-[[[6-methoxy-4-(7-quinolinylloxy)-7-quinazolinyl]oxy]methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288385-39-7 CAPLUS

CN 9H-Carbazole, 2-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 288385-86-4 CAPLUS


CN 1-Piperidineacetonitrile, 4-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 288386-17-4 CAPLUS


CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288386-24-3 CAPLUS

CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288386-27-6 CAPLUS

CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)



RN 288386-31-2 CAPLUS


CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288386-32-3 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)


09/ 913,020




RN 288386-33-4 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-
(9CI) (CA INDEX NAME)



RN 288386-34-5 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 288386-36-7 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288386-68-5 CAPLUS
CN 2-Piperidinone, 4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-

09/ 913,020


quinazolinyl]oxy)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 288386-73-2 CAPLUS


CN 2-Propanol, 1-(diethylamino)-3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288386-77-6 CAPLUS


CN 7-Quinazolinol, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 288386-79-8 CAPLUS


CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288386-81-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 288386-88-9 CAPLUS

CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 288386-90-3 CAPLUS


CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 288386-92-5 CAPLUS

CN 1-Piperidineacetone nitrile, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)


09/ 913,020



RN 288386-94-7 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288386-97-0 CAPLUS

CN 1-Piperazineethanol, .alpha.-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy)methyl]-4-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288386-99-2 CAPLUS

CN 4-Morpholineethanol, .alpha.-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 913,020



RN 288387-01-9 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-03-1 CAPLUS

CN 2-Propanol, 1-(diethylamino)-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-05-3 CAPLUS

09/ 913,020

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-07-5 CAPLUS

CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-09-7 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(4-morpholinyl)propyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 913,020



RN 288387-11-1 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(4-methyl-1-piperazinyl)propyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-13-3 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(1-pyrrolidinyl)propyl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 913,020



RN 288387-19-9 CAPLUS


CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288387-23-5 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-25-7 CAPLUS

CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 913,020



RN 288387-29-1 CAPLUS

CN 1-Pyrrolidineethanol, .alpha.-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-31-5 CAPLUS

CN 4-Morpholineethanol, .alpha.-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-33-7 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

09/ 913,020


Absolute stereochemistry.



RN 288387-35-9 CAPLUS

CN 2-Propanol, 1-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-37-1 CAPLUS

CN 2-Propanol, 1-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-41-7 CAPLUS

CN 1-Pyrrolidineethanol, .alpha.-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

09/ 913,020


Absolute stereochemistry.



RN 288387-42-8 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-43-9 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-44-0 CAPLUS


09/ 913,020

CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288387-45-1 CAPLUS

CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




IT 288387-46-2P, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288387-47-3P, 6-Methoxy-4-(4-nitroindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288387-50-8P, 4-(4-Aminoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288387-51-9P, 6-Methoxy-7-(3-piperidinopropoxy)-4-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)quinazoline 288387-53-1P, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(4-piperidinylpiperidino)propoxy]quinazoline 288387-55-3P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-((1-methyl-2-oxopyrrolidin-5-yl)methoxy)quinazoline 288387-57-5P, (S)-4-(1H-Indol-5-yloxy)-6-methoxy-7-((2-oxopyrrolidin-5-yl)methoxy)quinazoline 288387-59-7P, (R)-4-(1H-Indol-5-yloxy)-6-methoxy-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288387-60-0P, 6-Methoxy-4-[1-(3-piperidinopropyl)-1H-indol-5-yloxy]-7-(3-piperidinopropoxy)quinazoline 288387-61-1P, 6,7-Dimethoxy-4-(2-methyl-1H-benzimidazol-6-yloxy)quinazoline 288387-62-2P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinazolin-7-yloxy)quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(angiogenesis inhibitor; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)


RN 288387-46-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)


09/ 913,020




RN 288387-47-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(4-nitro-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288387-50-8 CAPLUS
CN 1H-Indol-4-amine, 5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 288387-51-9 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 288387-53-1 CAPLUS
CN Quinazoline, 7-(3-[1,4'-bipiperidin]-1'-ylpropoxy)-4-(1H-indol-5-yloxy)-6-

09/ 913,020


methoxy- (9CI) (CA INDEX NAME)



RN 288387-55-3 CAPLUS

CN 2-Pyrrolidinone, 5-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-methyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-57-5 CAPLUS

CN 2-Pyrrolidinone, 5-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-59-7 CAPLUS

CN 2-Pyrrolidinone, 5-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 913,020




RN 288387-60-0 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-piperidiny)propoxy]-4-[[1-[3-(1-piperidiny)propyl]-1H-indol-5-yl]oxy]-(9CI) (CA INDEX NAME)




RN 288387-61-1 CAPLUS

CN Quinazoline, 6,7-dimethoxy-4-[(2-methyl-1H-benzimidazol-5-yl)oxy]-(9CI) (CA INDEX NAME)




RN 288387-62-2 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-(7-quinazolinyl)oxy-(9CI) (CA INDEX NAME)




IT **288384-07-6P**, 7-Hydroxy-4-(indol-5-yloxy)-6-methoxyquinazoline
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)
 RN **288384-07-6** CAPLUS
 CN **7-Quinazolinol, 4-(1H-indol-5-yloxy)-6-methoxy-** (9CI) (CA INDEX NAME)




IT **288383-77-7P**, 7-(2-Carboxyvinyl)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288383-85-7P**, 7-Hydroxy-4-(2-methylindol-5-yloxy)quinazoline **288383-87-9P**, 7-Benzoyloxy-4-(2-methylindol-5-yloxy)quinazoline **288383-91-5P**, 4-(2,3-Dimethylindol-5-yloxy)-7-hydroxy-6-methoxyquinazoline **288383-93-7P**, 7-Benzoyloxy-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline **288384-60-1P**, 7-(2,3-Epoxypropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline **288385-08-0P**, 6-Methoxy-7-(3-morpholinopropoxy)-4-[(1-tert-butoxycarbonyl-1,2,3,4-tetrahydroquinolin-6-yl)oxy]quinazoline **288385-15-9P**, 4-[(1-tert-Butoxycarbonyl-2,3-dihydroindol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline **288385-24-0P**, 4-[(1-tert-Butoxycarbonyl-2,3-dihydroindol-5-yl)oxy]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline **288386-37-8P**, (R)-7-[2-Acetoxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline **288386-71-0P**, (R)-6-Methoxy-4-(2-methylindol-5-yloxy)-7-(oxiran-2-ylmethoxy)quinazoline **288386-75-4P**, 7-Benzoyloxy-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline **288387-21-3P**, (R)-4-(Indol-5-yloxy)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazoline **288387-27-9P**, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazoline **288387-39-3P**, (S)-6-Methoxy-4-(2-methylindol-5-yloxy)-7-(oxiran-2-ylmethoxy)quinazoline **288387-52-0P**, 7-(3-Bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxyquinazoline
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)
 RN **288383-77-7** CAPLUS
 CN **2-Propenoic acid, 3-[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]-** (9CI) (CA INDEX NAME)

09/ 913,020




RN 288383-85-7 CAPLUS

CN 7-Quinazolinol, 4-[(2-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 288383-87-9 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 288383-91-5 CAPLUS


CN 7-Quinazolinol, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy- (9CI) (CA INDEX NAME)



RN 288383-93-7 CAPLUS


CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)

09/ 913,020




RN 288384-60-1 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(oxiranylmethoxy)-
(9CI) (CA INDEX NAME)



RN 288385-08-0 CAPLUS


CN 1(2H)-Quinolinecarboxylic acid, 3,4-dihydro-6-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 288385-15-9 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

09/ 913,020




RN 288385-24-0 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 288386-37-8 CAPLUS
CN 1-Pyrrolidineethanol, .alpha.-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, acetate (ester), (.alpha.R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 288386-71-0 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)


09/ 913,020

Absolute stereochemistry.



RN 288386-75-4 CAPLUS


CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(phenylmethoxy)-
(9CI) (CA INDEX NAME)



RN 288387-21-3 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2R)-oxiranylmethoxy]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-27-9 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2S)-oxiranylmethoxy]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 913,020



RN 288387-39-3 CAPLUS


CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(2S)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-52-0 CAPLUS

CN Quinazoline, 7-(3-bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)




IT 288383-83-5, 6-Methoxy-4-((2-methylindol-5-yl)oxy)-7-[2-(N-methyl-N-tert-butoxycarbonylamino)ethoxy]quinazoline

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; prepn. of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN 288383-83-5 CAPLUS

CN Carbamic acid, [2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:353190 CAPLUS

DOCUMENT NUMBER: 125:33670

TITLE: Preparation of spiroalkyl group-containing heterocyclic pesticides and agrochemical fungicides

INVENTOR(S): Schaper, Wolfgang; Preus, Rainer; Braun, Peter; Kern, Manfred; Knauf, Werner; Sachse, Burkhard; Sanft, Ulrich; Waltersdorfer, Anna; Bonin, Werner; et al.

PATENT ASSIGNEE(S): Hoechst Schering Agrevo GmbH, Germany

SOURCE: Ger. Offen., 70 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4436509	A1	19960418	DE 1994-4436509	19941013
WO 9611924	A1	19960425	WO 1995-EP3927	19951005
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2202459	AA	19960425	CA 1995-2202459	19951005
AU 9538039	A1	19960506	AU 1995-38039	19951005
EP 785934	A1	19970730	EP 1995-935903	19951005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CN 1161037	A	19971001	CN 1995-195636	19951005
BR 9509308	A	19971104	BR 1995-9308	19951005
HU 77203	A2	19980302	HU 1997-1850	19951005
JP 10507187	T2	19980714	JP 1995-512898	19951005
US 5859009	A	19990112	US 1995-540987	19951011
ZA 9508594	A	19960523	ZA 1995-8594	19951012

PRIORITY APPLN. INFO.:

DE 1994-4436509



WO 1995-EP3927

19941013

19951005

OTHER SOURCE(S): MARPAT 125:33670

GI



AB The title compds. [I; A = CH, N; E = direct bond, (un)branched alkanediyl; R1 = H, halogen, alkyl, cycloalkyl, etc.; R2, R3 = H, halogen, alkyl, haloalkyl, cycloalkyl, alkoxy, etc.; R4, R5 = halogen, alkyl, haloalkyl, alkoxy, etc.; R6 = alkyl, alkenyl, alkynyl, (un)substituted aryl, (un)substituted heterocyclyl, OH, CO2H, etc.; U = direct bond, O, S, SO, SO2, (un)substituted NH; V = (un)substituted carbonyl derivs., etc.; W = (CH2)n; n = 1-4; X = NH, O, S, SO, SO2; Y, Z = CH2, O, S, SO, SO2; a, b = 0-3; r, s = 0-2] (e.g., II), useful as insecticides, acaricides, nematocides, and agrochem. fungicides, are prepd.


IT 177551-06-3P 177551-18-7P 177551-23-4P
177551-35-8P 177551-36-9P 177551-37-0P
177551-38-1P 177551-39-2P 177551-54-1P
177551-59-6P

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiroalkyl group-contg. heterocyclic pesticides and agrochem. fungicides)

RN 177551-06-3 CAPLUS

CN Quinazoline, 4-[[2-[(1-methylethoxy)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]oxy]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 177551-18-7 CAPLUS


CN Quinazoline, 4-[(3,3-dimethyl-1,5-dioxaspiro[5.5]undec-9-yl)oxy]- (9CI)
(CA INDEX NAME)

09/ 913,020



RN 177551-23-4 CAPLUS


CN Quinazoline, 4-[(3-ethyl-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl)oxy]-
(9CI) (CA INDEX NAME)



RN 177551-35-8 CAPLUS

CN Quinazoline, 4-[[2-(ethoxymethyl)-1,4-dioxaspiro[4.5]dec-8-yl]oxy]-, cis-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 177551-36-9 CAPLUS

CN Quinazoline, 4-[[2-[(1,1-dimethylethoxy)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]oxy]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




09/ 913,020

RN 177551-37-0 CAPLUS


CN Quinazoline, 4-[[2-[(1,1-dimethylethoxy)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 177551-38-1 CAPLUS

CN Quinazoline, 4-[(3-methyl-3-propyl-1,5-dioxaspiro[5.5]undec-9-yl)oxy]- (9CI) (CA INDEX NAME)



RN 177551-39-2 CAPLUS

CN Quinazoline, 4-[(3,3-diethyl-1,5-dioxaspiro[5.5]undec-9-yl)oxy]- (9CI) (CA INDEX NAME)




RN 177551-54-1 CAPLUS

CN Quinazoline, 4-[[2-[(1-methylethoxy)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 913,020




RN 177551-59-6 CAPLUS
CN Quinazoline, 4-[[2-(ethoxymethyl)-1,4-dioxaspiro[4.5]dec-8-yl]oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1986:199594 CAPLUS
DOCUMENT NUMBER: 104:199594
TITLE: The synthesis and biological properties of the derivatives of 4-heterylmercaptoquinazoline
AUTHOR(S): Sinyak, R. S.; Mazur, I. A.; Stets, V. R.; Martynovskii, A. A.; Steblyuk, P. N.
CORPORATE SOURCE: Zaporozh. Med. Inst., Zaporozhe, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1986), 20(2), 168-71
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 104:199594
GI



AB Nine title compds. (I; R = quinolyl, nitroquinolyl, chloromethylpurinyl, or substituted acridinyl) were prepd. by reaction of 4-chloroquinazoline [5190-68-1] with 2-mercaptoquinoline [2637-37-8] or with mercaptoacridines, or by reaction of 4-mercaptoquinazoline [3337-86-8] with 4-methoxy-9-chloroacridine [16492-15-2], 5-nitro-8-chloroquinoline

[22539-55-5], or 2,6-dichloro-7-methylpurine [2273-93-0]. Analgesic activity in mice was exhibited in I with a 5-nitroquinolin substituent or with an acridine ring substituted in the 2-position. Substitution with 5-nitroquinoline also reduced I toxicity. Various I exhibited anti-inflammatory and sleep-prolonging activity in mice, and some I displayed antimicrobial activity in vitro. Various structure-activity relations of I are discussed.


IT 102244-03-1P 102244-04-2P 102244-06-4P
102244-07-5P 102244-08-6P 102244-09-7P
102244-10-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and biol. activity of, structure in relation to)


RN 102244-03-1 CAPLUS

CN Quinazoline, 4-(2-quinolinylthio)- (9CI) (CA INDEX NAME)



RN 102244-04-2 CAPLUS


CN Quinazoline, 4-[(5-nitro-8-quinolinyl)thio]- (9CI) (CA INDEX NAME)




RN 102244-06-4 CAPLUS .

CN Acridine, 2-methoxy-9-(4-quinazolinylthio)- (9CI) (CA INDEX NAME)


09/ 913,020



RN 102244-07-5 CAPLUS
CN Acridine, 2-ethoxy-9-(4-quinazolinylthio)- (9CI) (CA INDEX NAME)




RN 102244-08-6 CAPLUS
CN Acridine, 2-chloro-9-(4-quinazolinylthio)- (9CI) (CA INDEX NAME)




RN 102244-09-7 CAPLUS
CN Acridine, 4-methoxy-9-(4-quinazolinylthio)- (9CI) (CA INDEX NAME)

09/ 913,020




RN 102244-10-0 CAPLUS
CN Acridine, 5-methoxy-3-nitro-9-(4-quinazolinylthio)- (9CI) (CA INDEX NAME)




L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:34492 CAPLUS
DOCUMENT NUMBER: 100:34492
TITLE: The synthesis of some quinazoline derivatives and their biological properties
AUTHOR(S): Karminski, W.; Kulicka, J.; Miernik, J.
CORPORATE SOURCE: Inst. Org. Chem. Technol., Silesian Polytech. Univ., Gliwice, Pol.
SOURCE: Journal of Environmental Science and Health, Part B: Pesticides, Food Contaminants, and Agricultural Wastes (1983), B18(4-5), 599-610
CODEN: JPFCD2; ISSN: 0360-1234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 100:34492
AB Fifteen 4-substituted-, 7 2,4-disubstituted-, and 5 2,4,6,8-tetrasubstituted-quinazolines were prepd. and tested for herbicidal, insecticidal, acaricidal, and fungicidal activity. All were ineffective except for 4-chloroquinazoline, which showed mild fungicidal activity.
IT **88404-41-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and herbicidal-insecticidal activities of)
RN 88404-41-5 CAPLUS
CN Quinazoline, 4,4'-thiobis- (9CI) (CA INDEX NAME)

09/ 913,020



IT **88404-40-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., herbicidal, and pesticidal activity of)
RN 88404-40-4 CAPLUS
CN Quinazoline, 4,4'-oxybis- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:51:55 ON 07 JAN 2004)

FILE 'REGISTRY' ENTERED AT 13:52:16 ON 07 JAN 2004

L1 STRUCTURE UPLOADED

L2 389 S L1 FUL

FILE 'CAPLUS' ENTERED AT 13:52:57 ON 07 JAN 2004

L3 8 S L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:54:29 ON 07 JAN 2004